[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Western Galilee Hospital-Nahariya\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":346},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,41,69,100,125,149,169,198,226,253,277,304,324],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100616883","local-subcutaneous-gentamicin-for-prevention-of-surgical-site-infection-after-elective-cesarean-section-100616883",false,"NCT07311395","Local Subcutaneous Gentamicin for Prevention of Surgical Site Infection After Elective Cesarean Section","Local Subcutaneous Administration of Gentamicin for the Prevention of Surgical Site Infection Following Elective Cesarean Section: A Randomized Controlled Pilot Study.","Inclusion Criteria:\n\n* Women aged 18 years and older.\n* Undergoing elective cesarean section.\n* Gestational age \\>= 24 weeks.\n* Planned postoperative follow-up of 30 days.\n* Eligible for standard antibiotic prophylaxis according to institutional protocol.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy of hypersensitivity to aminoglycosides.\n* Known allergy of hypersensitivity to systemic antibiotic prophylaxis agents.\n* Current or planned use of immunomodulatory or immunosuppressive therapy.\n* Requirement for therapeutic ( non- prophylactic) antibiotic treatment at the time of surgery.\n* Active infection or clinical condition requiring antibiotic treatment.\n* Inability or unwillingness to comply with study procedures or follow-up.",true,"FEMALE","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate whether local subcutaneous administration of gentamicin reduces the incidence of surgical site infection (SSI) following elective cesarean section. The study will also assess the safety of local gentamicin administration. The main questions this study aims to answer are:\n\n* Does local subcutaneous administration of gentamicin reduce the rate of superficial and deep surgical site infections within 30 days after elective cesarean delivery?\n* Are there differences between groups in postoperative complications, including wound healing, fever, need for additional antibiotic treatment, or hospital readmission?\n\nResearchers will compare women who receive local subcutaneous gentamicin at the surgical site in addition to standard antibiotic prophylaxis to women who receive standard antibiotic prophylaxis alone.\n\nParticipants will:\n\n* Undergo an elective cesarean section according to standard clinical practice\n* Receive either local subcutaneous gentamicin administration or no local antibiotic administration, in addition to standard systemic antibiotic prophylaxis\n* Be followed clinically for signs of surgical site infection and other postoperative complications during hospitalization and at follow-up visits up to 30 days after surgery",[27],"Surgical Site Infection","RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":32},"2025-12-08",{"date":36,"type":21},"2027-01-07",{"name":38,"class":39},"Western Galilee Hospital-Nahariya","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100560561","validation-testing-for-plasma-oxalate-levels-in-the-biochemical-laboratory-at-the-galilee-medical-center-in-collaboration-with-the-biochemistry-laboratory-at-charite-hospital-in-berlin-and-testing-the-relationship-between-oxalate-levels-and-vitamin-c-levels-in-plasma-100560561","NCT06578754","Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in Collaboration With the Biochemistry Laboratory at CHARITE Hospital in Berlin, and Testing the Relationship Between Oxalate Levels and Vitamin C Levels in Plasma","Validation Test for Plasma Oxalate Level in a Biochemical Laboratory at the Galilee Medical Center","Inclusion Criteria:\n\n* Signing the informed consent\n\nExclusion Criteria:\n\n* Not willing to participate","ALL","1 Minute","80 Years",{"count":52,"type":21},50,"1 Year","OBSERVATIONAL","Background:\n\nElevated plasma oxalate levels in various conditions, including: primary hyperoxaluria due to increased production in the liver, renal failure due to decreased renal excretion, intestinal diseases with fatty diarrhea due to increased intestinal absorption, and increased intake of substances containing oxalate or sources of oxalate. Primary hyperoxaluria type 1 is a rare hereditary disease in which there is an increase in oxalate production in the liver due to a defect in the AGT enzyme in the oxalate metabolism pathway. The disease causes end-stage renal failure, and until recently, the only treatment was liver and kidney transplantation. The disease is more common in our region, and the Pediatric Nephrology Unit is a center of expertise for this disease. In 2022, a new treatment for hyperoxaluria type 1, which is an alternative to liver transplantation (Lomecirane), was added to the health basket. With the introduction of this treatment in Israel, there was a need to test the level of oxalate in plasma in order to monitor the response to treatment and as part of the preparation for kidney transplantation in cases of type 1 hyperoxaluria with end-stage renal failure. There is no laboratory in Israel that performs plasma oxalate testing. The biochemistry laboratory at the Galilee Medical Center performs oxalate testing in urine using an enzymatic method. Testing for oxalate in plasma using this method requires external validation because the manufacturer intends this test for urine only. There are laboratories around the world that use this method to measure oxalate in plasma.\n\nVitamin C is a precursor (source) for oxalate in the body. High vitamin C levels in dialysis may lead to increased oxalate, which is associated with worsening kidney damage and damage to other organs, including an increase in the incidence of cardiovascular disease. Dialysis patients are therefore advised to avoid vitamin C supplements. On the other hand, cases of symptomatic vitamin C deficiency in dialysis patients have been described due to their tendency to have an inadequate diet. One case was described in the literature by the Nephrology Department at our institution.\n\nObjectives:\n\n1. To validate the plasma oxalate test by comparing it to an external laboratory that performs the test.\n2. To examine the relationship between vitamin C levels and plasma oxalate levels in patients with varying degrees of renal failure.\n\nImportance:\n\n1. Establishment of a laboratory service that does not currently exist in Israel and is clinically important for treatment decisions.\n2. Assessing the relationship between vitamin C levels and oxalate levels in renal failure will help in the tailored treatment of these patients and prevent complications of vitamin C deficiency on the one hand or hyperoxaluria secondary to vitamin C excess on the other.",[57],"Hyperoxaluria",[59],"plasma oxalate level, hyperoxaluria","NOT_YET_RECRUITING","2026-05-03",{"date":63,"type":32},"2026-05-07",{"date":65,"type":21},"2026-08-01",{"date":67,"type":21},"2027-12-01",{"name":38,"class":39},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100634187","phase-4-preoperative-indomethacin-and-paracetamol-for-pain-management-during-oocyte-retrieval-in-ivf-patients-100634187","NCT07536425","Preoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients","Evaluating the Efficacy of Preoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients A Randomized Controlled Study","Inclusion Criteria:\n\n* Women undergoing oocyte retrieval for IVF or ICSI\n* Age 18-45 years\n* ASA physical status classification I or II\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to Indomethacin, any NSAID, or Paracetamol\n* History of gastrointestinal bleeding or peptic ulceration\n* Renal impairment (GFR \\\u003C 30 ml\u002Fmin\u002F1.73m² or Creatinine \\> 1.04 mg\u002FdL)\n* Hepatic impairment (ALT \\> 55 U\u002FL, AST \\> upper limit of normal, ALP \\> upper limit of normal, Total Bilirubin \\> 1.2 mg\u002FdL, or Albumin \\\u003C 3.5 g\u002FdL)\n* Participation in another clinical trial that may interfere with the outcomes of this study","45 Years",{"count":78,"type":21},177,[80],"PHASE4","This is a randomized controlled trial evaluating the efficacy of preoperative analgesic medications - Indomethacin (100 mg per rectum) and Paracetamol\u002FAcamol (1,000 mg intravenously) - for pain management during oocyte retrieval in women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).",[83,84],"Pain","Oocyte Retrieval",[86,87,88,89,90,91],"Oocyte retrieval","IVF","ICSI","Pain management","Assisted reproductive technology","Numerical Rating Scale","2026-04-27",{"date":94,"type":32},"2026-05-04",{"date":96,"type":21},"2026-04-13",{"date":98,"type":21},"2027-12-31",{"name":38,"class":39},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100632754","phase-4-iv-papavrine-for-labor-induction-in-term-prom-100632754","NCT07517796","I.V Papavrine for Labor Induction in Term PROM","I.V Papavrine for Labor Induction in Term PROM: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* • Singleton pregnancy\n\n  * Term gestation (37-42 weeks)\n  * Term PROM prior to active labor\n  * Duration of PROM \\\u003C12 hours at enrollment\n  * Bishop score \\\u003C8\n  * Cephalic presentation\n  * Viable fetus with reassuring fetal heart rate\n\nExclusion Criteria:\n\n* • Multiple gestation\n\n  * Previous cesarean delivery\n  * Major fetal anomalies\n  * Contraindication to vaginal delivery\n  * Meconium-stained amniotic fluid\n  * Suspected chorioamnionitis",{"count":108,"type":21},110,[80],"This prospective randomized controlled trial aims to evaluate whether intravenous administration of papaverine 12 hours after term PROM reduces the interval from membrane rupture to delivery and improves maternal and neonatal outcomes. Researchers will compare drug papaverine to a placebo",[112],"Premature Rupture of Membranes",[114,115,116],"premature rupture of membranes","papaverine","bishop score","2026-04-03",{"date":119,"type":32},"2026-04-08",{"date":121,"type":32},"2025-10-22",{"date":123,"type":21},"2027-10-22",{"name":38,"class":39},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100620104","carbetocin-vs-misoprostol-for-postpartum-hemorrhage-prevention-100620104","NCT07353281","Carbetocin vs Misoprostol for Postpartum Hemorrhage Prevention","Carbetocin Versus Misoprostol for the Prevention of Postpartum Hemorrhage After Vaginal Delivery in Women With Risk Factors: A Prospective Randomized Study","Inclusion Criteria\n\n* Women aged 18 years or older\n* Singleton pregnancy\n* Gestational age 37-42 weeks\n* Cephalic presentation\n* Vaginal delivery\n* Presence of one or more risk factors for postpartum hemorrhage, including:\n* Grand multiparity (≥5 previous deliveries)\n* History of postpartum hemorrhage\n* History of manual removal of placenta\n* Estimated fetal weight ≥4,000 grams\n* Polyhydramnios\n* Chorioamnionitis\n* Prolonged oxytocin use during labor (third augmentation cycle or more)\n* Eligible for prophylactic uterotonic therapy after delivery\n* Provided written informed consent\n\nExclusion Criteria\n\n* Multiple gestation\n* Known major fetal anomalies\n* Intrauterine fetal demise (IUFD)\n* Contraindication to vaginal delivery\n* Known hypersensitivity to carbetocin, misoprostol, or oxytocin\n* Known coagulation disorders requiring alternative management\n* Planned cesarean delivery\n* Participation in another interventional study that may affect postpartum bleeding outcomes",{"count":133,"type":21},146,[24],"Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality worldwide, particularly among women with known risk factors. Uterotonic agents are routinely administered after vaginal delivery to prevent excessive bleeding. Carbetocin, a long-acting oxytocin analogue, and misoprostol are both used for this purpose, but comparative data in high-risk vaginal deliveries remain limited.\n\nThis prospective randomized study aims to compare the effectiveness and safety of intravenous carbetocin versus rectal misoprostol for the prevention of postpartum hemorrhage in women with risk factors undergoing vaginal delivery at Galilee Medical Center. The primary outcome is the incidence of postpartum hemorrhage. Secondary outcomes include the need for additional uterotonic agents or surgical interventions, changes in hemoglobin levels, blood transfusion requirements, and maternal adverse effects.",[137,138],"Postpartum Complication","Postpartum Hemorrhage",[140],"Postpartum hemorrhage, Carbetocin, Misoprostol, Vaginal delivery, Uterotonic agents, High-risk pregnancy","2026-01-13",{"date":143,"type":32},"2026-01-20",{"date":145,"type":21},"2026-01-31",{"date":147,"type":21},"2028-01-01",{"name":38,"class":39},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":168,"locationsCount":4},"100617365","combined-nipple-stimulation-and-foley-balloon-for-cervical-ripening-100617365","NCT07317674","Combined Nipple Stimulation and Foley Balloon for Cervical Ripening","The Effect of Nipple Stimulation Combined With Foley Balloon Catheter on Bishop Score and Induction-to-delivery Interval: a Prospective Randomized Trial","Inclusion Criteria:\n\n* Pregnant individuals aged ≥18 years\n* Singleton pregnancy\n* Term gestation (37-42 weeks)\n* Cephalic fetal presentation\n* Intact membranes\n* Bishop score \\\u003C6 at enrollment\n* Medical indication for labor induction\n\nExclusion Criteria:\n\n* Multiple gestation\n* Previous cesarean delivery or uterine surgery\n* Contraindication to vaginal delivery\n* Major fetal anomalies\n* Active labor at enrollment\n* Unstable fetal lie or presentation\n* Contraindication to Foley balloon catheter insertion\n* Conditions precluding nipple stimulation (e.g., local breast infection, prior breast surgery involving the nipple)",{"count":20,"type":21},[24],"Labor induction rates have increased substantially worldwide, and successful cervical ripening remains a key determinant of induction outcomes. Mechanical cervical ripening with a Foley balloon catheter is widely used and considered safe, while nipple stimulation promotes endogenous oxytocin release and represents a physiologic method for stimulating uterine contractions. However, the combined effect of nipple stimulation and balloon catheter use has not been systematically evaluated.\n\nThis prospective, randomized, double-blinded controlled trial will assess whether the addition of nipple stimulation to Foley balloon catheter cervical ripening improves Bishop score and shortens the induction-to-delivery interval compared with balloon catheter alone. Term pregnant patients (37-42 weeks' gestation) with a singleton, cephalic pregnancy and an unfavorable cervix (Bishop score \\\u003C6) requiring labor induction will be randomized to receive either Foley balloon catheter plus standardized nipple stimulation or Foley balloon catheter alone.\n\nThe primary outcomes are change in Bishop score after catheter removal and time from catheter insertion to delivery. Secondary outcomes include need for additional induction methods, mode of delivery, maternal and neonatal outcomes, pain, patient satisfaction, and breastfeeding rates. The study aims to evaluate the efficacy and safety of incorporating a physiologic intervention into standard mechanical cervical ripening.",[160,161],"Induction of Labor","Cervical Ripening","2025-12-19",{"date":164,"type":32},"2026-01-05",{"date":166,"type":21},"2026-01-01",{"date":147,"type":21},{"name":38,"class":39},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":40},"100475365","comparing-two-prophylactic-antibiotic-protocols-in-women-with-term-prolonged-pre-labor-rupture-of-membrane-and-preterm-labor-100475365","NCT05469984","Comparing Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor","Comparing Obstetrical Outcomes and Infectious Morbidity Between Two Prophylactic Antibiotic Protocols in Women With Term Prolonged Pre-labor Rupture of Membrane and Preterm Labor","Inclusion Criteria: maternal age \\> 18 years singleton pregnancy vertex presentation prolonged \\>18 h prom or preterm delivery\n\n\\-\n\nExclusion Criteria:\n\n* GBS carrier\n* preterm premature rupture of membrane for conservative treatment\n* intra-uterine fetal death fetal major anomaly\n* drug allergy for the antibiotic in use in this study\n* women receiving antibiotic treatment for other infection such as urinary tract infection","48 Years",{"count":178,"type":21},600,[24],"This randomized prospective trial aimed to compare 2 prophylactic antibiotic regiment (ampicillin alone versus ampicillin plus gentamycin) in term prolonged pre-labor rupture of membrane and in preterm deliveries and examine related obstetrical outcome and infectious morbidity",[182,183],"Preterm Labor With Preterm Delivery","Premature Rupture of Membranes Prolonged",[185,186,187,188,189],"prolonged term PROM","pre-term labor","prophylactic antibiotic","peripartum infection","bacterial distribution","2025-08-05",{"date":192,"type":32},"2025-08-06",{"date":194,"type":32},"2022-11-25",{"date":196,"type":21},"2025-09-26",{"name":38,"class":39},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":40},"100581340","comparing-infectious-morbidity-among-women-with-meconium-stained-amniotic-fluid-at-term-between-those-treated-with-prophylactic-antibiotics-zinacef-vs-placebo-100581340","NCT06849037","Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo","and Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Who Will be Treated With Prophylactic Antibiotics Zinacef vs. Placebo","Inclusion Criteria:\n\n* singleton pregnancy at term\n* meconium-stained amniotic fluid\n\nExclusion Criteria:\n\n* Intrauterine fetal death\n* GBS carriers\n* zinacef allergy\n* antibiotic treatment for other indication",{"count":206,"type":21},182,[24],"Our randomized controlled double blind clinical trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo.",[210,211],"Meconium-stained Amniotic Fluid","Chorioamnionitis",[213,214,215,216,217],"meconium-stained amniotic fluid","antibiotic treatment","infectious morbidity","chorioamnionitis","zinacef","2025-07-16",{"date":220,"type":32},"2025-07-20",{"date":222,"type":32},"2025-02-18",{"date":224,"type":21},"2029-02-13",{"name":38,"class":39},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":40},"100590164","evaluation-of-microbial-and-endocrinological-parameters-in-dialysis-patients-with-sepsis-100590164","NCT06963853","Evaluation of Microbial and Endocrinological Parameters in Dialysis Patients With Sepsis","Inclusion Criteria: hemodialysis patients over the age of 18 who are hospitalized at the Galilee Medical Center due to sepsis and have provided written informed consent to participate in this study.\n\n\\-\n\nExclusion Criteria: • Patients with cognitive impairment who are unable to provide informed consent.\n\n\\-",{"count":233,"type":21},200,"This prospective study aims to evaluate the diagnostic value and reliability of blood cultures obtained from different sources-central venous catheter (CVC), dialysis machine, and peripheral vein-in hemodialysis patients with suspected catheter-related bloodstream infections (CRBSIs). By comparing the timing and rates of bacterial growth from each site, the study seeks to identify the most accurate and timely method for diagnosing bloodstream infections in this patient population.\n\nIn addition, the study will assess the dynamics of parathyroid hormone (PTH) levels during acute infections. Specifically, it will investigate whether a significant drop in PTH levels-and the rate of recovery following infection-correlates with adverse outcomes such as infectious complications, cardiovascular morbidity, or 90-day mortality. These findings may offer valuable prognostic insights and support improved monitoring and treatment strategies for dialysis patients experiencing infection.",[236,237],"Sepsis","Hemodialysis",[239,240,241,242,243,244],"blood cultures","parathyroid hormone","catheter","infection","cardiovascular","mortality","2025-05-09",{"date":247,"type":32},"2025-05-14",{"date":249,"type":32},"2022-08-16",{"date":251,"type":21},"2027-12",{"name":38,"class":39},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":40},"100585171","comparison-of-sonographic-and-mri-weight-estimation-in-fetuses-with-suspected-macrosomia-100585171","NCT06898892","Comparison of Sonographic and MRI Weight Estimation in Fetuses with Suspected Macrosomia","Comparison of the Accuracy of Fetal Weight Estimation Between Sonographic Vs. Magnetic Resonance Assessment","Inclusion Criteria:\n\nsingleton pregnancy at term, suspected fetal macrosomia,\n\nExclusion Criteria:\n\n* fetal anomaly multiple pregnancy PROM","50 Years",{"count":262,"type":21},80,[24],"The goal of this clinical trial is to compare the accuracy of sonographic vs. magnetic resonance fetal weight estimation in suspected fetal macrosomia in term pregnancy.\n\nPregnant patient at term with suspected macrosomia will participate and undergo both sonographic and magnetic resonance fetal weight estimations and the actual birthweight will be recorded and compared with the fetal weight estimations",[266],"Accuracy of Sonographic Vs MRI Fetal Weight Estimation",[268],"fetal weight estimation, accuracy","2025-03-25",{"date":271,"type":32},"2025-03-27",{"date":273,"type":32},"2025-02-13",{"date":275,"type":21},"2028-02-13",{"name":38,"class":39},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":16,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":287,"conditions":288,"keywords":291,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":40},"100579255","impact-of-antiglycemic--immunosuppressive-therapies-on-netosis-in-diabetes--kidney-disease-nets---neutrophil-traps-100579255","NCT06821919","Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)","Evaluating the Effect of Hemodialysis Modality and New Anti-glycemic Drugs on NETosis on in Hemodialysis and Diabetic Patient, and Assessment of NETosis in Various Kidney Diseases","NETs","Inclusion Criteria:\n\nDM therapy study: - Diabetic patients aged 18 years or older (men and women).\n\n* Patients who have not previously received SGLT2 inhibitors or GLP-1 receptor agonists.\n\n  -Chronic kidney disease (CKD) patients :50 CKD patients with various etiologies.\n\n  • Focus:\n* This part of the study will specifically evaluate immune-mediated kidney disease, such as ANCA-associated vasculitis, and the effects of immunosuppressive therapy on NETosis.\n\n  • Exclusion Criteria:\n* Patients with acute infections, hematologic or oncologic diseases, or positive for HIV or Hepatitis B\u002FC",{"count":286,"type":21},70,"This study aims to investigate whether new glucose-lowering medications, such as SGLT2 inhibitors (e.g., Forxiga\u002FJardiance) and GLP-1 receptor agonists (e.g., Ozempic), can reduce NETosis in diabetic patients, thereby mitigating secondary complications such as cardiovascular disease and kidney damage. By targeting dysregulated NET formation, the study seeks to establish a link between reduced NETosis and improved clinical outcomes in diabetes.\n\nAdditionally, the study will evaluate the effects of immunosuppressive therapies on NETosis in patients with immune-mediated kidney diseases, such as ANCA-associated vasculitis. By correlating NETosis activity with disease progression and treatment response, this research will assess whether reducing NETosis contributes to better management of inflammation and secondary morbidity in these conditions.\n\nThrough these evaluations, the study aims to identify potential therapeutic strategies to improve outcomes in both diabetic and chronic kidney disease populations.",[289,290],"Diabetes Mellitus","Kidney Disease",[292,293,294,295],"NETosis","Diabetes mellitus","kidney disease","glomerulonephritis","2025-02-10",{"date":298,"type":32},"2025-02-12",{"date":300,"type":32},"2024-05-13",{"date":302,"type":21},"2031-12-30",{"name":38,"class":39},{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":40},"100578663","phase-4-using-antibiotics-to-prevent-infections-in-hemodialysis-patients-during-catheter-placement-100578663","NCT06814223","Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement","Preventive Antibiotic Treatment Before Insertion or Exchange of Tunneled Cuffed Catheters in Hemodialysis Patients to Prevent Early Catheter-Related Infections","Inclusion Criteria:\n\n* Hemodialysis patients scheduled for new tunneled catheter placement or replacement of an existing tunneled catheter.\n* Prior diagnosis of at least one of the following conditions:\n\n  1. Atrial fibrillation\n  2. Heart failure\n  3. Femoral tunneled catheter\n\n     * Patients who have signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* • Hemodialysis patients unable to provide informed consent and requiring a legal guardian.\n\n  * Patients undergoing prolonged antibiotic therapy prior to tunneled catheter insertion.",{"count":233,"type":21},[80],"The goal of this clinical trial is to determine if prophylactic antibiotic treatment can reduce the incidence of early catheter-related infections in hemodialysis patients at high risk, including those with femoral catheter placement, atrial fibrillation, or heart failure.\n\nThe main questions it aims to answer are:\n\n1. Will prophylactic antibiotic administration reduce catheter-related infections by 50% within 45 days of catheter insertion?\n2. Will this intervention decrease the rate of secondary complications such as metastatic infections, cardiovascular morbidity, and mortality?\n\nResearchers will compare patients receiving prophylactic antibiotics (e.g., cefamezine and gentamicin, or vancomycin for high-risk individuals) to those not receiving antibiotics, to assess the difference in infection rates and associated complications.\n\nParticipants :\n\n* Be randomized into two groups: one receiving prophylactic antibiotics and one without antibiotics before catheter placement or replacement.\n* Undergo follow-up for 45 days to monitor for catheter-related infections and secondary complications.\n\nThis study will provide critical data to evaluate whether targeted prophylactic antibiotic treatment should become standard practice for high-risk hemodialysis patients.",[315],"Infection Catheter-Related","2025-02-05",{"date":318,"type":32},"2025-02-07",{"date":320,"type":32},"2024-10-28",{"date":322,"type":21},"2028-06-30",{"name":38,"class":39},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100558155","papaverine-and-oxytocin-vs-oxytocin-alone-in-labor-induction-100558155","NCT06547437","Papaverine and Oxytocin vs Oxytocin Alone in Labor Induction","\"Evaluating the Effectiveness of Papaverine as an Adjunct to Oxytocin for Labor Induction: A Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Women with a singleton pregnancy Over the age of 18 Term (between 37-42 weeks of gestation) A medical decision for labor induction using oxytocin. Cephalic presentation Viable fetus nulliparity\n\nExclusion Criteria:\n\n* parity \\>1\n* Twin pregnancy Women with a previous cesarean section Severe fetal anomalies Women with psychiatric disorders, including depression and schizophrenia. Contraindication to vaginal delivery Women unable to sign the consent form Women known to have SVT (supraventricular tachycardia). Women with a heart rate over 100 or arrhythmia Known sensitivity to any component of the drug Liver disease",{"count":332,"type":21},126,[24],"This study aims to evaluate the efficacy and safety of combining papaverine with oxytocin for labor induction compared to oxytocin alone",[336,337],"Induced; Birth","Labor Onset and Length Abnormalities","2024-09-10",{"date":340,"type":32},"2024-09-19",{"date":342,"type":21},"2024-09",{"date":344,"type":21},"2025-12",{"name":38,"class":39},""]